Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Ernest Mario sold 10,000 shares of the stock in a transaction on Monday, December 18th. The shares were sold at an average price of $3.57, for a total value of $35,700.00. Following the sale, the director now owns 10,000 shares of the company’s stock, valued at approximately $35,700. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Ernest Mario also recently made the following trade(s):

  • On Thursday, December 14th, Ernest Mario sold 1,967 shares of Tonix Pharmaceuticals stock. The shares were sold at an average price of $3.58, for a total value of $7,041.86.
  • On Thursday, December 21st, Ernest Mario sold 36,967 shares of Tonix Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $129,754.17.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) opened at $3.52 on Monday. The stock has a market capitalization of $26.91, a price-to-earnings ratio of -0.74 and a beta of 2.92. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $2.85 and a 52 week high of $9.40.

TNXP has been the subject of several analyst reports. Aegis reiterated a “buy” rating on shares of Tonix Pharmaceuticals in a report on Friday, December 1st. ValuEngine upgraded Tonix Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $8.33.

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Vanguard Group Inc. raised its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 184,377 shares of the company’s stock after buying an additional 41,264 shares during the period. Vanguard Group Inc. owned about 2.46% of Tonix Pharmaceuticals worth $799,000 at the end of the most recent quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.